Search Results - "Grinblatt, D"

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? by MEHTA, J, GORDON, L. I, SINGHAL, S, TALLMAN, M. S, WINTER, J. N, EVENS, A. O, FRANKFURT, O, WILLIAMS, S. F, GRINBLATT, D, KAMINER, L, MEAGHER, R

“…Sixty three patients aged 27-66 years (median 52) were allografted from HLA-matched sibling (n=47), 10 of 10 allele-matched unrelated (n=19), or…”
Get full text

249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY by Steensma, D, Abedi, M, Bejar, R, Cogle, C, Foucar, K, Garcia-Manero, G, George, T, Grinblatt, D, Komrokji, R, Maciejewski, J, Pollyea, D, Roboz, G, Savona, M, Scott, B, Sekeres, M, Thompson, M, Sugrue, M, Swern, A, Nifenecker, M, Erba, H

Get full text

P121 Patients with hematologic disorders receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry, achieve transfusion independence by Grinblatt, D, Narang, M, Malone, J, Sweet, D, Dunne, T, Sullivan, K

Get full text

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation by SINGHAL, S, GORDON, L. I, MEHTA, J, TALLMAN, M. S, WINTER, J. N, EVENS, A. O, FRANKFURT, O, WILLIAMS, S. F, GRINBLATT, D, KAMINER, L, MEAGHER, R

“…Whether the CD34+ and CD3+ cell doses in allogeneic HSCT should be estimated using actual (ABW) or ideal (IBW) body weight has never been definitively…”
Get full text

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? by Mehta, J, Gordon, L I, Tallman, M S, Winter, J N, Evens, A M, Frankfurt, O, Williams, S F, Grinblatt, D, Kaminer, L, Meagher, R, Singhal, S

Get full text

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation by Singhal, S, Gordon, L I, Tallman, M S, Winter, J N, Evens, A M, Frankfurt, O, Williams, S F, Grinblatt, D, Kaminer, L, Meagher, R, Mehta, J

Get full text

A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer by LAPORT, G. G, FLEMING, G. F, WAGGONER, S, ZIMMERMAN, T. M, GRINBLATT, D. L, WILLIAMS, S. F

“…As docetaxel is known to have significant antineoplastic activity against breast and ovarian cancer, we explored its application as a peripheral blood stem…”
Get full text

High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer : a 10-year experience by LAPORT, G. F, GRAD, G, GRINBLATT, D. L, BITRAN, J. D, WILLIAMS, S. F

“…One hundred women with metastatic breast cancer (MBC) underwent high-dose chemotherapy with autologous stem cell rescue at our institution beginning in 1986…”
Get full text

Autologous and allogeneic transplantation for aggressive NHL by Smith, S.M., Grinblatt, D., van Besien, K.

“…:Intermediate-and high-grade NHL are generally chemosensitive dis eases with high initial response rates to combination chemotherapy. Dose intensification via…”
Get full text

Azacitidine in Lower-Risk Myelodysplastic Syndromes: AMeta-Analysis of Data from Prospective Studies by Komrokji, R, Swern, AS, Grinblatt, D, Lyons, RM, Tobiasson, M, Silverman, LR, Sayar, H, Vij, R, Fliss, A, Tu, N

Get full text

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies by Komrokji, Rami, Swern, Arlene S., Grinblatt, David, Lyons, Roger M., Tobiasson, Magnus, Silverman, Lewis R., Sayar, Hamid, Vij, Ravi, Fliss, Albert, Tu, Nora, Sugrue, Mary M.

“…Background After erythropoiesis‐stimulating agent (ESA) failure, lenalidomide and hypomethylating agents are the only remaining treatment options for most…”
Get full text

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma by Zimmerman, Todd M., Grinblatt, David L., Malloy, Rebecca, Williams, Stephanie F.

“…BACKGROUND Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after…”
Get full text

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer by Laport, G.G., Valone, F.H., Zimmerman, T.M., Grinblatt, D.L., Van Vlasselaer, P., Still, B.J., Williams, S.F.

“…BDS60 is a novel buoyant density solution, whose density has been adjusted to enrich PBSC from subjects who have been mobilized with cytokines alone, or…”
Get full text

Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer by Lazarus, H M, Winton, E F, Williams, S F, Grinblatt, D, Campion, M, Cooper, B W, Gunn, H, Manfreda, S, Isaacs, R E

“…Our purpose was to determine the maximum tolerated dosage of rhIL-6 after high-dose cytotoxic chemotherapy and autologous BMT in patients with advanced breast…”
Get more information

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma by Zimmerman, Todd M., Michelson, Glenn C., Mick, Rosemarie, Grinblatt, David L., Williams, Stephanie F.

“…A subgroup of patients with refractory Hodgkin's (HD) or non‐Hodgkin's (NHL) lymphoma may be cured with high‐dose chemotherapy and peripheral blood progenitor…”
Get full text

Response of pancreatic carcinoma to 5-fluorouracil and leucovorin by Grinblatt, D L, Benson, 3rd, A B

Get more information

Patients with secondary myelodysplastic syndromes (MDS) who are enrolled in AVIDA, a longitudinal registry for patients receiving azacitidine (AZA) by Grinblatt, D. L., Narang, M., Malone, J. M., Sweet, D. A., Dunne, T. S., Sullivan, K. A.

“…Abstract only 7094 Background: Prevalence of secondary MDS (sMDS) is increasing because of improved survival of patients treated with chemotherapy or…”
Get full text

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies by Mehta, J., Frankfurt, O., Altman, J., Evens, Andrew M, Gordon, L., Tallman, M., Williams, S., Winter, J., Krishnamurthy, J., Grinblatt, D., Kaminer, L., Singhal, S.

“…130 patients who were unsuitable for conventional-intensity conditioning underwent RI-HSCT after 100 mg/m2 melphalan (+ 50 mg/kg cyclophosphamide if no prior…”
Get full text

Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT by Singhal, Seema, Evens, A., Frankfurt, O., Gordon, L., Meagher, R., Tallman, M., Williams, S., Winter, J., Grinblatt, D., Kaminer, L., Mehta, J.

“…Graft CD34+ cell content based on ABW affects outcome after conventional allografts (Singhal et al. BMT 2000; 26:489–96). Engraftment after autologous (Ali et…”
Get full text

Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics by Mehta, Jayesh, Evens, A., Frankfurt, O., Gordon, L., Grinblatt, D., Kaminer, L., Meagher, R., Tallman, M., Williams, S., Winter, J., Singhal, S.

“…Our aim was to identify pre-transplant variables affecting the outcome of submyeloablative HSCT in 63 patients (27–66 y, median 52) with NHL/Hodgkin/CLL…”
Get full text